Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

l-2 proteins, restoring cell death to cancerous cells. Additionally, the compounds were found to enhance the effects of chemotherapy and radiation used to treat other types of cancer, such as non-small cell lung cancer.

Kinase Inhibitors (ABT-869)

Many oncology researchers are currently developing agents that target kinases, a class of enzymes that are often overly activated in cancer cells. Inhibition of the appropriate kinases can suppress tumor growth by cutting off its blood supply.

Discovered by Abbott scientists, ABT-869 is an oral small molecule that provides simultaneously potent and specific inhibition of the VEGFR and PDGFR families that is in Phase I clinical trials for solid tumors and selected hematologic malignancies such as leukemia. Phase II trials for several tumor types began this year.

PARP Inhibitors (ABT-888)

DNA damaging agents remain some of the most successful treatments for cancer. The enzyme Poly(ADP-ribose)polymerase (abbreviated PARP) can help repair DNA damage caused by these agents used to treat cancer and render them ineffective. As PARP activity is often increased in cancer cells, it provides these cells with a survival mechanism.

ABT-888 is an oral PARP-inhibitor developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents.

ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I trials. Preclinical data indicates ABT-888 has improved the effectiveness of radiation and many types of chemotherapy in animal models of cancer.

About Abbott Oncology

Abbott Oncology is committed to the discovery and development of innovative cancer treatments that enable patients to live longer and healthier lives. Abbott's oncology research is focused on developing more targeted, less toxic therapies than are cu
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 2015 Atagi Plastic Surgery and Skin ... an Ultherapy® Ultra Treatment Provider by Ulthera, ... Aesthetics is one of only six practices in Colorado ... provider. , Atagi Plastic Surgery and Skin Aesthetics’ ... has led the practice to earn the distinction of ...
(Date:6/1/2015)... The Muscular Dystrophy Association is offering an ... the sold out 2015 Bank of America Chicago ... by signing up through the organization's nationwide endurance ... , This national endurance program includes world-class training ... a supportive community of teammates, volunteers, coaches and ...
(Date:6/1/2015)... Note: Dr. Julian is available for interviews ... , A phase III trial funded by the National ... carcinoma in situ (DCIS) now have an additional tool ... (NSABP B-35/NRG Oncology) looked at more than 3,000 DCIS ... with tamoxifen to those who completed five years of ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Northridge ... are now offering patients a promotion on Invisalign for ... of Invisalign treatment is reduced to $3,700. Patients can ... the complimentary consultation and discuss the extent of correction ... it cannot be combined with any other offer. ...
(Date:6/1/2015)... InstantLabs will co-develop and commercialize a ... a Cooperative Research and Development Agreement (CRADA) with the ... with U.S. Farm Bill legislation, only members of the ... the United States. , InstantLabs’ DNA-based technology will ... need rather than requiring samples be sent to centralized ...
Breaking Medicine News(10 mins):Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Sold Out 2015 Bank of America Chicago Marathon and Marine Corps Marathon Entries Still Available through MDA Team Momentum 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 4
... 2011 Egocentric, self-centred, and insensitive to the needs ... with severe traumatic brain injury (TBI) and have been ... the capacity to recognise and understand the emotions of ... more common, and resulting empathy deficits can have negative ...
... Maryland, June 28, 2011 Nurses on a surgical ... center cut bloodstream infections to zero and saved more ... of Maryland Medical Center SICU sustained a rate of ... period, eliminating 14 CLABSIs and saving 2-3 lives when ...
... from Wayne State University, and her mentor, Lisa J. Rapport, ... Liberal Arts and Sciences, found that if traumatic brain injury ... help them rehabilitate. The study was recently published in ... disruption of normal brain function after a head injury and ...
... Americans and the rest of the nation have been ... blacks who identify as members of the Seventh-day Adventist ... the average American. Researchers point to certain lifestyle behaviors ... was conducted at Loma Linda University as part of ...
... today,s society where access to media is ever present, many ... children and how media consumption can potentially affect them. Two ... and Dr. Michelle M. Garrison, PhD of Seattle Children,s Research ... media usage can lead to depression in college students and ...
... battle to lose inches or at least stay the same, ... 25 and 27 at the American Diabetes Association,s Scientific Sessions ... Epidemiologists from the School of Medicine at The ... showing that diet soft drink consumption is associated with increased ...
Cached Medicine News:Health News:Lack of empathy following traumatic brain injury linked to reduced responsiveness to anger 2Health News:Intensive, hands-on effort reduces bloodstream infections in critically ill patients 2Health News:Religion benefits traumatic brain injury victims, Wayne State University research finds 2Health News:Black members of Adventist church defy health disparities, study shows 2Health News:Studies examine impact of media use among youth, recommend preventative measures 2Health News:Studies examine impact of media use among youth, recommend preventative measures 3Health News:Related studies point to the illusion of the artificial 2Health News:Related studies point to the illusion of the artificial 3
(Date:6/1/2015)... About Pressure Relief Devices ... and improve the quality life of patients who suffer ... a significant role in inhibiting the growth and treatment ... turn or rotate an immobile patient by providing all ... and specialty beds. These devices have the ability to ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
(Date:6/1/2015)... MENLO PARK, Calif. , June ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... clinical trial of  VAL-083  (dianhydrogalactitol) in patients with ... deadly form of human brain cancer. ...
Breaking Medicine Technology:Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8